VistaGen Therapeutics Inc Earnings

The next earnings date for VistaGen Therapeutics Inc has not yet been scheduled.

Analyst Estimates of VistaGen Therapeutics Inc Earnings

No Results.
Report DateEstimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

VistaGen Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/11/2025After Market$-0.47-6.82%
02/11/2025Before Market$-0.4611.54%
11/07/2024After Market$-0.42-7.69%
08/13/2024After Market$-0.3512.50%
06/11/2024After Market$-0.2530.56%
02/13/2024After Market$-0.2226.67%
11/09/2023After Market$-0.662.94%
08/10/2023After Market$-0.94-2,273.74%
06/28/2023After Market$-1.75-16.67%
02/07/2023After Market$-0.0528.57%
11/10/2022After Market$-0.08-14.29%
08/11/2022After Market$-0.10-42.86%
06/23/2022After Market$-0.09-50.00%
02/10/2022After Market$-0.0528.57%
11/10/2021After Market$-0.07-16.67%
08/12/2021After Market$-0.0420.00%
06/29/2021After Market$-0.20-300.00%
02/11/2021After Market$-0.07-40.00%
11/12/2020After Market$-0.05-150.00%
08/13/2020After Market$-0.0741.67%
06/29/2020After Market$-0.0712.50%
02/13/2020After Market$-0.15-114.29%
11/07/2019Before Market$-0.130.00%
08/13/2019After Market$-0.15-36.36%
06/25/2019After Market$-0.17-41.67%
02/12/2019After Market$-0.24-14.29%
10/29/2018After Market$-0.30-76.47%
08/14/2018After Market$-0.20-42.86%
06/26/2018After Market$-0.0978.05%
02/12/2018After Market$-0.2365.67%
11/09/2017After Market$-0.53-39.47%
08/14/2017After Market$-0.2839.13%
06/29/2017Before Market$-0.3138.00%
02/13/2017After Market$-0.348.11%
11/14/2016After Market$-0.42-10.53%
08/12/2016After Market$-0.518.93%
06/24/2016After Market$-4.44-146.67%
02/16/2016After Market$-1.9569.67%
11/16/2015Before Market$-5.26---
08/14/2015After Market$-19.23---
06/29/2015After Market$-5.49-553.57%
02/17/2015After Market$-1.08---
11/19/2014After Market$-1.90---
08/12/2014After Market$-3.70---
03/31/2014---$-47.12---
12/31/2013---$-13.23---
09/30/2013---$-40.49---
06/30/2013---$-13.10---
03/31/2013---$-111.78---
12/31/2012---$-408.70---
09/30/2012---$-69.67---
06/30/2012---$-65.05---
03/31/2012---$-123.85---
12/31/2011---$-168.38---
09/30/2011---$-88.82---
06/30/2011---$-134.26---

More About VistaGen Therapeutics Inc

Website
https://www.vistagen.com
Country
USA
Full Time Employees
57

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

“VistaGen Therapeutics Inc Earnings” Can Refer to the VistaGen Therapeutics Inc Earnings Date

Some people say “VistaGen Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my VistaGen Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning VistaGen Therapeutics Inc Stock on the Earnings Date

If you own VistaGen Therapeutics Inc stock (VTGN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for VistaGen Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading VistaGen Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More VistaGen Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about VistaGen Therapeutics Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.